Lumida
/STOK
⌘K
Stoke Therapeutics Inc

Stoke Therapeutics Inc

STOK
$29.03USD-1.06%-0.31 today

MARKET CAP

1.9B

P/E (TTM)

FWD P/E

DAY RANGE

$29 – $30

52W RANGE

$20
$40

AI Summary

Stalk
Sell NowHigh

STOK is entrenched in a Stage 4 decline following a high-volume support failure beneath the 29.65 zone, confirming a new downtrend with lower highs and lower lows under declining EMAs. Medium-term bias remains bearish as price trades below the 9/20/50 EMA cluster, and short-term bounces into the 30.00 6.00 6031.00 zone have been rejected, with momentum still negative and no mean-reversion eligibility. The optimal engagement is to sell now into structural resistance on any rally.

  • 74% convulsive seizure reduction in interim Zoriva-Nursen trials
  • $411M cash runway into 2028 ensures Phase III funding
  • Net loss of $38.3M in Q3 elevates cash burn risk
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$12.4M$8.8M$36.6M$184.4M
YoY %-29.2%+316.3%+404.5%
P / Sales28.5x29.4x16.3x10.2x
EV / Sales25.1x15.4x14.0x10.1x
Gross Profit, Adj.$12.4M$8.8M$36.6M$184.4M
YoY %-29.2%+316.3%+404.5%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit25.1x15.4x14.0x10.1x
EBITDA, Adj.$-102.8M$-112.3M$-99.2M$-18.8M
YoY %-22.6%-9.2%+11.7%+81.0%
Margin %-828.8%-1279.1%-271.4%-10.2%
EV / EBITDA-3.0x-1.2x-5.1x-98.9x
EBIT$-104.4M$-114.8M$-101.4M$-20.6M
YoY %-21.3%-10.0%+11.7%+79.7%
Margin %-841.2%-1307.2%-277.3%-11.2%
EV / EBIT-3.0x-1.2x-5.0x-90.4x
Net Income$-101.1M$-104.7M$-89.0M$-6.9M
YoY %-17.8%-3.6%+15.0%+92.3%
Net Margin-814.7%-1192.5%-243.4%-3.7%
EPS (GAAP)-$2.60-$2.38-$1.65-$0.12
YoY %-11.1%+8.5%+30.7%+92.7%